Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram, fluoxetine, and Vitagnus for premenstrual dysphoric disorder
IRCT20150630022991N13Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in Premenstrual Dysphoric Disorder (PMDD) comparing Escitalopram arm, Vitagnus arm and Fluoxetine control arm (3 arms). Primary endpoint: Severity of premenstrual symptoms. Started Aug 2018; status: completed.
02
Drugs
escitalopramfluoxetinePremens
03
Conditions
Premenstrual Dysphoric Disorder (PMDD)
Beyond the preview
Go deeper on IRCT20150630022991N13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20150630022991N13.